What the Department of Labor’s Final PBM Fee Disclosure Rule Means for Plan Sponsors

Est. Reading Time: 3 min

The U.S. Department of Labor (DOL) has released its final Pharmacy Benefit Manager (PBM) Fee Disclosure Rule, expanding what plan sponsors can see and verify about PBM compensation. The rule requires PBMs and their affiliated consultants to disclose compensation arrangements, financial incentives, and potential conflicts of interest. It also gives plans broader access to the records supporting those disclosures.

What the Rule Requires

The rule applies primarily to large, self-insured group health plans and takes effect 60 days after publication in the Federal Register. Its requirements apply to plan years beginning on or after July 1, 2027, with most employers likely to see the primary impact in 2028.

Compensation disclosures

PBMs must report compensation at least twice per year, compare actual compensation with previously disclosed estimates, and explain material variances.

Disclosures cover:

  • Direct compensation from the employer or plan
  • Rebates and manufacturer payments
  • Spread pricing arrangements
  • Pharmacy recoupment and claw-back arrangements
  • Price protection agreements
  • Formulary placement incentives
  • Drug pricing methodologies
  • Contract termination compensation
  • Other indirect revenue from throughout the supply chain

Audit rights

Plans can conduct annual audits to validate PBM disclosures and choose their own independent auditor without PBM restrictions. They can also obtain supporting records, transaction-level data, contracts, and compensation arrangements generally within 60 days.

From Disclosure to Accountability

The rule specifies what PBMs must disclose but does not require a standardized format. Plan sponsors may receive hundreds of pages of compensation schedules, rebate arrangements, and transaction-level reports that vary in structure and detail, meeting disclosure requirements while leaving plan economics difficult to interpret.

Because PBMs self-report the information, sponsors need to validate its accuracy and reasonableness. Without that context, more information can create complexity rather than clarity.

Audit rights give sponsors a way to test what the disclosures show. An independent audit can help answer practical questions:

  • How are rebates passed back to the plan?
  • How are administrative fees charged for different services?
  • How are claims directed to PBM-owned pharmacies?

Contract performance can shift throughout the year, and issues may emerge well before the next review. Pairing independent audits with market benchmarking and ongoing claim monitoring helps plan sponsors test disclosures against actual results and catch discrepancies as the PBM processes claims, not just at year-end reconciliation.

What Plan Sponsors Should Assess and Do Now

For self-insured employers, greater visibility creates an opportunity to assess whether PBM compensation is reasonable, contractual commitments align with actual performance, and financial incentives influence benefit decisions.

Disclosures from brokers, consultants, and other organizations providing pharmacy benefit services give employers a clearer view of the economic relationships behind benefit decisions. Plan sponsors can use that insight to identify financial incentives that warrant scrutiny and evaluate whether advisor recommendations align with the interests of the plan and its participants.

To put that visibility into practice, plan sponsors can:

  • Mark the timeline. Plan around the July 1, 2027 applicability date, with the primary impact on most employers likely in 2028.
  • Review your audit rights. Examine current contract terms for auditor selection, record access, and audit frequency.
  • Ask your PBM about delivery. Find out how your PBM will provide disclosures and in what format, recognizing that formats may vary.
  • Clarify advisor compensation. Understand how your PBM pays affiliated brokers or consultants.
  • Connect disclosures to performance data. Bring disclosure review together with claims monitoring and benchmarking to validate findings.

Frequently Asked Questions

What is the DOL’s final PBM Fee Disclosure Rule?
It requires PBMs and their affiliated brokers and consultants to disclose compensation, financial incentives, and potential conflicts of interest to large, self-insured group health plans. It also expands those plans’ audit rights.

When do the requirements apply?
They apply to plan years beginning on or after July 1, 2027. Most employers will likely see the primary impact in 2028.

How often must PBMs report compensation?
At least twice per year. PBMs must also explain material variances from previously disclosed estimates.

Can a PBM choose or limit the auditor?
No. Plans choose their own auditor, without PBM restrictions on that choice.

Why do plan sponsors need to validate disclosures?
The information is self-reported by PBMs, and the rule does not require a standardized format. Independent review helps sponsors confirm accuracy and reasonableness.

Does disclosure alone create accountability?
No. Accountability depends on how plan sponsors interpret the information, validate it, and act on what they find.

Truveris will continue monitoring further guidance from the Department of Labor and share updates as plan sponsors prepare for the July 1, 2027 applicability date.

See a demo.

Contact our team today to see how Truveris’ technology and expertise could revolutionize your pharmacy benefits program.